Evidence map›Paper›PMID 38837106›Full record

ReviewCurrent oncology reports2024

From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.

Joshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, Sijie Yao, G Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu and 6 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Advances in the management of localized bladder cancers.Nature reviews. Clinical oncology · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Joshua A Linscott *Department of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Joshua.linscott@moffitt.org.
Hiroko Miyagi *Department of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Prithvi B MurthyDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Sijie YaoDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
G Daniel GrassDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Aram VosoughiDepartment of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Hongzhi XuDepartment of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Xuefeng WangDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Xiaoqing YuDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Alice YuDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Logan ZempDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Scott M GilbertDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Michael A PochDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Wade J SextonDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Philippe E SpiessDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Roger LiDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review sought to define the emerging roles of urinary tumor DNA (utDNA) for diagnosis, monitoring, and treatment of bladder cancer. Building from early landmark studies the focus is on recent studies, highlighting how utDNA could aid personalized care. RECENT

findingsRecent research underscores the potential for utDNA to be the premiere biomarker in bladder cancer due to the constant interface between urine and tumor. Many studies find utDNA to be more informative than other biomarkers in bladder cancer, especially in early stages of disease. Points of emphasis include superior sensitivity over traditional urine cytology, broad genomic and epigenetic insights, and the potential for non-invasive, real-time analysis of tumor biology. utDNA shows promise for improving all phases of bladder cancer care, paving the way for personalized treatment strategies. Building from current research, future comprehensive clinical trials will validate utDNA's clinical utility, potentially revolutionizing bladder cancer management.

Indexed as

Biomarkers, TumorDNA, NeoplasmUrinary Bladder NeoplasmsHumansPrecision MedicineBiomarkers, TumorDNA, NeoplasmBladder cancerCell-free DNACirculating tumor DNALiquid biopsyPrecision oncologyUrinary biomarkersUrinary tumor DNAUrothelial cancer

Identifiers

PMID38837106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.